Benazeprilat  (Synonyms: CGS 14831)

Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage^[1][2][3].

Benazeprilat (10 mg/kg, intravenous injection) and amlodipine (0.5 mg/kg, intravenous injection) in combination produce great hypotensive effect^[2].
Benazepril (0.7 mg/kg, oral) markedly influences the dynamics of systemic RAAS peptides, resulting in a substantial decrease in AII and ALD while increasing PRA and AI^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

396.44

C₂₂H₂₄N₂O₅

86541-78-8

固体

White to off-white

贝那普利EP杂质C

Room temperature in continental US; may vary elsewhere.

• [1]. Barrios V, Antihypertensive and organ-protective effects of benazepril. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1653-71.  [Content Brief]

  [2]. Bazil MK, Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1993 Mar;21(3):405-11.  [Content Brief]

  [3]. Mochel JP, Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. J Vet Pharmacol Ther. 2013 Apr;36(2):174-80.  [Content Brief]